JP2016539168A5 - - Google Patents

Download PDF

Info

Publication number
JP2016539168A5
JP2016539168A5 JP2016536746A JP2016536746A JP2016539168A5 JP 2016539168 A5 JP2016539168 A5 JP 2016539168A5 JP 2016536746 A JP2016536746 A JP 2016536746A JP 2016536746 A JP2016536746 A JP 2016536746A JP 2016539168 A5 JP2016539168 A5 JP 2016539168A5
Authority
JP
Japan
Prior art keywords
formula
compound
steps
following
synthesizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016536746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539168A (ja
JP6454707B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/076041 external-priority patent/WO2015082370A1/en
Publication of JP2016539168A publication Critical patent/JP2016539168A/ja
Publication of JP2016539168A5 publication Critical patent/JP2016539168A5/ja
Application granted granted Critical
Publication of JP6454707B2 publication Critical patent/JP6454707B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016536746A 2013-12-05 2014-12-01 trans−8−クロロ−5−メチル−1−[4−(ピリジン−2−イルオキシ)−シクロヘキシル]−5,6−ジヒドロ−4H−2,3,5,10b−テトラアザ−ベンゾ[e]アズレン及びその結晶形態の合成 Active JP6454707B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13195864.7 2013-12-05
EP13195864 2013-12-05
PCT/EP2014/076041 WO2015082370A1 (en) 2013-12-05 2014-12-01 Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof

Publications (3)

Publication Number Publication Date
JP2016539168A JP2016539168A (ja) 2016-12-15
JP2016539168A5 true JP2016539168A5 (enExample) 2018-08-09
JP6454707B2 JP6454707B2 (ja) 2019-01-16

Family

ID=49726573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016536746A Active JP6454707B2 (ja) 2013-12-05 2014-12-01 trans−8−クロロ−5−メチル−1−[4−(ピリジン−2−イルオキシ)−シクロヘキシル]−5,6−ジヒドロ−4H−2,3,5,10b−テトラアザ−ベンゾ[e]アズレン及びその結晶形態の合成

Country Status (19)

Country Link
US (3) US10246460B2 (enExample)
EP (1) EP3077396B1 (enExample)
JP (1) JP6454707B2 (enExample)
KR (3) KR102384630B1 (enExample)
CN (1) CN105793263B (enExample)
AR (1) AR098592A1 (enExample)
AU (2) AU2014359409A1 (enExample)
CA (2) CA3142754C (enExample)
ES (1) ES2875411T3 (enExample)
HR (1) HRP20210966T1 (enExample)
IL (2) IL245450A0 (enExample)
MX (1) MX372971B (enExample)
MY (1) MY175464A (enExample)
NZ (1) NZ720340A (enExample)
PL (1) PL3077396T3 (enExample)
SG (1) SG11201604502SA (enExample)
SI (1) SI3077396T1 (enExample)
WO (1) WO2015082370A1 (enExample)
ZA (1) ZA201603304B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105793263B (zh) * 2013-12-05 2019-08-23 豪夫迈·罗氏有限公司 一种苯并[e]薁化合物及其晶型的合成
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
BR112020004035A2 (pt) * 2017-12-08 2020-09-01 F. Hoffmann-La Roche Ag formulação farmacêutica
WO2020139670A1 (en) 2018-12-27 2020-07-02 Teva Pharmaceuticals International Gmbh Solid state forms of balovaptan
US20240154207A1 (en) 2021-10-06 2024-05-09 Lg Energy Solution, Ltd. Battery module

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1197242A (en) * 1983-03-02 1985-11-26 Jean A. Gauthier Pyrimido¬1,2-a|pyrrolo¬2,1-c|¬1, 4|benzodiazepine-3-carboxylic acid derivatives
RS20050638A (sr) * 2003-02-19 2007-12-31 Pfizer Inc., Triazolska jedinjenja korisna u terapiji
GB0303852D0 (en) 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
GB0400700D0 (en) 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
CA2578370A1 (en) 2004-08-25 2006-03-02 Pfizer Inc. Triazolobenzodiazepines and their use as vasopressin antagonists
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
PL2358714T3 (pl) * 2008-11-18 2012-12-31 Hoffmann La Roche Etery alkilocykloheksylowe dihydrotetraazabenzoazulenu
SG171846A1 (en) * 2008-11-28 2011-07-28 Hoffmann La Roche Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists
US8492376B2 (en) 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
JP6427192B2 (ja) 2013-08-19 2018-11-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 位相変位睡眠障害を処置するためのV1aアンタゴニスト
CN105793263B (zh) * 2013-12-05 2019-08-23 豪夫迈·罗氏有限公司 一种苯并[e]薁化合物及其晶型的合成

Similar Documents

Publication Publication Date Title
JP2019194236A5 (enExample)
JP2018024670A5 (enExample)
JP2018536572A5 (enExample)
JP2019048806A5 (enExample)
JP2016520672A5 (enExample)
JP2018521020A5 (enExample)
JP2009149903A5 (enExample)
JP2017008120A5 (enExample)
JP2013532130A5 (enExample)
IL256624A (en) Pharmaceuticals and their pharmaceutical preparations for the treatment of inflammatory disorders
JP2018024682A5 (enExample)
JP2011105738A5 (enExample)
JP2016153424A5 (enExample)
JP2012111758A5 (enExample)
JP2011527560A5 (enExample)
JP2011520976A5 (enExample)
JP2013032389A5 (enExample)
JP2011518833A5 (enExample)
JP2020515557A5 (enExample)
JP2018030858A5 (enExample)
JP2019089762A5 (enExample)
JP2014526533A5 (enExample)
JP2018150298A5 (enExample)
JP2015129106A5 (enExample)
JP2016513122A5 (enExample)